BioLife Solutions (NASDAQ:BLFS) Issues Earnings Results

Key Points

• BioLife Solutions beat Q1 expectations, reporting earnings of $0.02 per share and revenue of $27.5 million, both above consensus estimates. The company also posted a positive return on equity of 1.83% despite a negative net margin.
• Revenue growth was strong, with Q1 sales up 25% year over year and adjusted EBITDA of $6.2 million, or 22% of revenue. Management said biopreservation media (BPM) remains the main growth driver and represents more than 85% of revenue.
• The company reaffirmed full-year 2026 guidance of $112.5 million to $115 million in revenue and expects mid-60s gross margins and full-year GAAP net income. However, temporary bag yield issues are weighing on margins now, with recovery expected by late 2026 or early 2027.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) announced its earnings results on Thursday. The medical equipment provider reported $0.02 earnings per share for the quarter, beating the consensus estimate of $0.01 by $0.01, FiscalAI reports. BioLife Solutions had a positive return on equity of 1.83% and a negative net margin of 2.80%.The company had revenue of $27.50 million for the quarter, compared to the consensus estimate of $25.66 million.

Here are the key takeaways from BioLife Solutions' conference call:

• Q1 revenue was $27.5 million, up 25% year‑over‑year, with adjusted EBITDA of $6.2 million (22% of revenue); biopreservation media (BPM) drove growth and represents over 85% of revenue with top 20 BPM customers providing strong visibility.
• Bag yield issues pressured gross margin (adjusted gross margin down to 64% from 68%) and adjusted EBITDA percentage; management says the issue is temporary, customer notifications and a 90‑day selection window are underway, and margin recovery is expected by Q4 2026 or Q1 2027 depending on inventory burn.
• The company reaffirmed 2026 guidance of $112.5M–$115M revenue (17%–20% growth), expects mid‑60s gross margins, and anticipates achieving full‑year GAAP net income and expanded adjusted EBITDA margins for 2026.
• BioLife is expanding beyond BPM — including CellSeal, hPL, the award‑winning CryoCase, and a planned PanTHERA Q4 launch — and says cross‑selling these products could raise revenue per dose by 2 to 3 times versus BPM alone.

BioLife Solutions Trading Down 4.7%

Shares of NASDAQ:BLFS traded down $1.08 during midday trading on Friday, hitting $22.04. 722,105 shares of the stock were exchanged, compared to its average volume of 370,784. BioLife Solutions has a twelve month low of $17.86 and a twelve month high of $29.62. The company has a 50 day moving average price of $20.36 and a 200-day moving average price of $23.34. The stock has a market cap of $1.08 billion, a P/E ratio of -275.47 and a beta of 1.97.

Key BioLife Solutions News

Here are the key news stories impacting BioLife Solutions this week:

• Positive Sentiment: BioLife reported Q1 2026 revenue of $27.5 million, up 25% year over year, with GAAP net income of $1.2 million and adjusted EBITDA of $6.2 million, showing improved profitability and operational leverage. BioLife Solutions Reports First Quarter 2026 Financial Results
• Positive Sentiment: The company beat earnings expectations, posting $0.04 per share versus the $0.01 consensus estimate, while revenue also came in above forecasts at $27.5 million versus $25.66 million expected. BioLife Solutions, Inc. (BLFS) Tops Q1 Earnings and Revenue Estimates
• Positive Sentiment: BioLife also updated FY2026 revenue guidance to $112.5 million-$115.0 million, which brackets the market consensus near $113.0 million and suggests management still sees steady full-year demand. BioLife Solutions earnings transcript
• Neutral Sentiment: Analysts continue to rate BLFS a “Moderate Buy,” reinforcing a constructive long-term outlook but not signaling a major new catalyst. BioLife Solutions Receives Consensus Recommendation of Moderate Buy from Analysts
• Neutral Sentiment: A comparison article versus Organigram Global added little directly relevant new information for BLFS investors. Head-To-Head Contrast: Organigram Global versus BioLife Solutions

Insiders Place Their Bets

In other BioLife Solutions news, insider Karen A. Foster sold 96,923 shares of BioLife Solutions stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $20.15, for a total transaction of $1,952,998.45. Following the completion of the transaction, the insider owned 113,742 shares in the company, valued at approximately $2,291,901.30. The trade was a 46.01% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In the last ninety days, insiders have sold 99,641 shares of company stock worth $2,009,000. Company insiders own 2.20% of the company's stock.

Hedge Funds Weigh In On BioLife Solutions

Several hedge funds have recently bought and sold shares of the stock. T. Rowe Price Investment Management Inc. raised its holdings in shares of BioLife Solutions by 27.4% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 5,180,824 shares of the medical equipment provider's stock worth $125,273,000 after acquiring an additional 1,113,972 shares during the last quarter. Invesco Ltd. increased its position in BioLife Solutions by 9.2% during the 4th quarter. Invesco Ltd. now owns 3,932,191 shares of the medical equipment provider's stock worth $95,080,000 after purchasing an additional 332,747 shares in the last quarter. State Street Corp raised its stake in BioLife Solutions by 3.4% in the 4th quarter. State Street Corp now owns 1,505,593 shares of the medical equipment provider's stock valued at $36,405,000 after purchasing an additional 49,028 shares during the last quarter. Ameriprise Financial Inc. lifted its holdings in BioLife Solutions by 11.3% in the 2nd quarter. Ameriprise Financial Inc. now owns 1,080,371 shares of the medical equipment provider's stock valued at $23,271,000 after purchasing an additional 109,959 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in BioLife Solutions by 2.2% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,025,170 shares of the medical equipment provider's stock valued at $24,791,000 after purchasing an additional 21,787 shares in the last quarter. Hedge funds and other institutional investors own 93.24% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on BLFS shares. Zacks Research upgraded shares of BioLife Solutions from a "hold" rating to a "strong-buy" rating in a report on Friday, January 23rd. Wall Street Zen upgraded shares of BioLife Solutions from a "hold" rating to a "buy" rating in a research report on Saturday, February 28th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of BioLife Solutions in a research report on Monday, April 20th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, BioLife Solutions presently has an average rating of "Moderate Buy" and a consensus price target of $32.00.

BioLife Solutions Company Profile

BioLife Solutions NASDAQ: BLFS specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife's product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company's flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.